Evaxion Biotech Files 6-K Report

TL;DR

Evaxion Biotech filed a 6-K, just routine reporting for Danish biotech.

AI Summary

Evaxion Biotech A/S filed a Form 6-K on January 15, 2025, to report information for the month of January 2025. The company is a foreign private issuer based in Hoersholm, Denmark, and is subject to the 1934 Securities Exchange Act. Evaxion Biotech A/S is incorporated in G7 and its fiscal year ends on December 31.

Why It Matters

This filing indicates ongoing reporting requirements for Evaxion Biotech A/S as a foreign private issuer, providing transparency to investors about its regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a standard periodic report and does not contain new material financial or operational information that would inherently increase risk.

Key Players & Entities

• Evaxion Biotech A/S (company) — Registrant
• 001-39950 (company) — Commission File Number
• 20250115 (date) — Filing Date
• Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (company) — Principal Executive Office Address

FAQ

From the Filing

0001171843-25-000260.txt : 20250115 0001171843-25-000260.hdr.sgml : 20250115 20250115081032 ACCESSION NUMBER: 0001171843-25-000260 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20250115 FILED AS OF DATE: 20250115 DATE AS OF CHANGE: 20250115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion Biotech A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 25531218 BUSINESS ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 BUSINESS PHONE: 004531262615 MAIL ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 6-K 1 f6k_011525.htm FORM 6-K   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]      Form 40-F [   ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.  --> INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), and Form F-1 (File No. 333-283304), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Press Release On January 15, 2025, Evaxion Biotech A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled “Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01”. A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K. Exhibits Exhibit No.   Description       99.1   Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the unde